Compare Invesco NASDAQ 100 ETF (QQQM) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco NASDAQ 100 ETF vs Repligen Corporation Common Stock — how do they compare? Invesco NASDAQ 100 ETF trades at $296.5 (market cap $111.60B), while Repligen Corporation Common Stock trades at $178.85 (market cap $11.31B). The key difference: Invesco NASDAQ 100 ETF is far larger — about 9.9× Repligen Corporation Common Stock's market cap, and Invesco NASDAQ 100 ETF is more actively traded (3,716,107 versus 1,216,919). Which is the better fit depends on your goals — on Pluang, investors hold Invesco NASDAQ 100 ETF for 56 Days and Repligen Corporation Common Stock for 0 Days on average.
| QQQM | RGEN | |
|---|---|---|
Market Cap | $111.60B | $11.31B |
Volume | 3,716,107 | 1,216,919 |
Sector | Broad Market / Factor | Health |
52-Week High | $312.76 | $194.57 |
52-Week Low | $229.87 | $102.87 |
Typical Hold Time | 56 Days | 0 Days |
Enterprise Value | — | $11.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QQQM trades at $306.18, down 0.33% on the day, with a bullish technical signal from moving averages while oscillators remain neutral. The ETF maintains its focus on Nasdaq-100 exposure with a competitive 0.15% expense ratio. Recent institutional buying includes QRG Capital Management increasing its position by 207.5% during Q2 2026, signaling confidence in the fund's strategy.
The outlook remains positive given the Nasdaq-100's strong performance and institutional accumulation, though risks include market concentration in technology stocks and potential volatility. The fund's lower fees compared to QQQ provide a structural advantage for long-term investors seeking Nasdaq exposure.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Invesco NASDAQ 100 ETF
QQQM is an ETF designed to track the performance of the NASDAQ-100 Index. It provides exposure to the 100 largest non-financial companies listed on the NASDAQ. Positioned as a lower-cost and more long-term-investor-friendly alternative to its peer QQQ, QQQM offers the same fundamental market exposure but typically has a lower share price and is structured to appeal to investors focused on accumulation rather than active trading.
Read more on QQQM →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
